Adherium, an Australian digital health company focused on respiratory diseases, has received the US Food and Drug Administration (FDA) approval for its Hailie Smartinhaler.

The Smartinhaler is designed to be compatible with AstraZeneca’s Airsupra and Breztri inhalation devices.

Airsupra is an FDA-approved rescue medication for asthma patients and Breztri is a triple combination therapy for chronic obstructive pulmonary disease (COPD) patients.

Hailie Smartinhaler is a significant step forward in the management of asthma and COPD.

The device offers patients and healthcare providers enhanced monitoring capabilities and personalised treatment approaches, said the digital health company.

Adherium CEO Paul Mastoridis said: “Our mission at Adherium has always been to revolutionise the way respiratory conditions are managed.

“By securing FDA clearance for our Smartinhaler with Airsupra and Breztri, we’re bringing that vision to life, offering patients and healthcare providers a powerful tool in the fight against chronic respiratory diseases.”

According to Adherium, AstraZeneca’s Airsurpa and Breztri are at the forefront of respiratory care, providing patients with advanced treatment options.

Airsupra is transforming the rescue medication by providing as-needed inhaled corticosteroids and short-acting β2-agonist (ICS/SABA) asthma rescue and management treatment.

Breztri has shown significant benefits in reducing exacerbations in COPD patients.

Smartinhaler’s compatibility with Airsupra Breztri provides patients and clinicians with real-time data and insights into their medication usage patterns and inhaler technique feedback.

The approach is said to enhance overall treatment efficacy and improve patient outcomes.

Adherium said that Smartinhaler’s compatibility with Breztri will provide the company a 100% coverage for triple therapy inhalers in the US.

Allergist Bill McCann said: “The combination of the Hailie Smartinhaler with Airsupra and Breztri devices represents a leap forward in our ability to treat and manage asthma and COPD.

“This integration allows for a more nuanced understanding of patient needs and the ability to adjust treatments in real-time, which is invaluable in achieving optimal patient outcomes.”